// App-Quantinova.ai

TPS4596 : PDIGREE: An adaptive phase 3 trialof PD-inhibitor nivolumab andipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreatedrenal cell cancer(Alliance A031704).

Researchers

Presenter

  • Tian Zhang

Principal Investigators

  • Karla V. Ballman

  • Atish Dipankar Choudhury

  • Ronald C. Chen

  • Colleen Watt

  • Yujia Wen

  • Tyler Zemla

  • Hamid Emamekhoo

  • Shilpa Gupta

  • Michael J. Morris

  • Daniel J. George

  • Toni K. Choueiri

Medical Centers

  • Duke University Medical Center, Durham, NC

  • Weill Cornell Medicine, New York, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • University of North Carolina, Chapel Hill, NC

  • The University of Chicago Medical Center, Chicago, IL

  • Univ of Chicago, Chicago, IL

  • Mayo Clinic, Rochester, MN

  • University of Wisconsin School of Medicine and Public Health, Madison, WI

  • Department of Medicinal Chemistry and Masonic Cancer Center, University of Minnesota, Minneapolis, MN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Duke University Cancer Institute, Durham, NC

  • Dana-Farber-Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Interleukin 6

  • Vascular endothelial growth factor A

Drug/Treatment

  • Cabozantinib

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03793166

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved